NCT05989503View on ClinicalTrials.gov

Initiation of ARNi and SGLT2i in Patients With HFrEF

PHASE4CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

August 4, 2023

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
DRUG

Sacubitril-valsartan

Sacubitril-valsartan titration at the discretion of the treating physician

DRUG

SGLT2 inhibitor

Either empagliflozin or dapagliflozin 10 mg/day

Trial Locations (5)

4099-001

Centro Hospitalar Universitário de Santo António, Porto

4200-319

Centro Hospitalar Universitário São João, Porto

Faculty of Medicine (FMUP), Porto

4434-502

Centro Hospitalar Vila Nova de Gaia/Espinho, Porto

Unknown

Unidade Local de Saúde de Matosinhos - Hospital Pedro Hispano, Porto

All Listed Sponsors
collaborator

Unidade de Investigação e Desenvolvimento Cardiovascular (UnIC)

UNKNOWN

collaborator

Rede de Investigação em Saúde

OTHER

lead

Universidade do Porto

OTHER

NCT05989503 - Initiation of ARNi and SGLT2i in Patients With HFrEF | Biotech Hunter | Biotech Hunter